Humana Inc. reported solid results for the second quarter, with the Insurance segment's benefit ratio of 89.9% aligning with expected medical cost trends. The company's 2Q25 Adjusted EPS slightly exceeded expectations. Humana has improved its full-year 2025 outlook and remains focused on enhancing its Medicare Advantage $(MA)$ margin by delivering clinical excellence. The company is confident in the strong core fundamentals and growth prospects for MA and value-based care, emphasizing its commitment to effective competition and better outcomes for members and patients.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。